By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

TransMolecular, Inc. 

Corporate Office
840 Memorial Drive, Second Floor
Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-995-3050 Fax: 617-995-3049


SEARCH JOBS


Industry
Pharmaceutical






Company News
Morphotek Inc. Announces Acquisition of Tumor Targeting Assets From TransMolecular, Inc. 4/5/2011 8:45:00 AM
TransMolecular, Inc.'s 131I-TM601 Shown to Improve Survival in Recurrent Malignant Glioma 10/23/2009 8:31:02 AM
TransMolecular, Inc.'s 131I-TM601 Successfully Localizes to Multiple Tumor Types without Targeting Healthy Tissue 6/17/2009 9:25:10 AM
TransMolecular, Inc. Presents New Data Highlighting the Anti-angiogenic and Tumor-targeting Properties of TM601 at American Society of Clinical Oncology Annual Meeting 6/1/2009 9:16:41 AM
TransMolecular, Inc. Announces Presentation of Data Highlighting Anti-angiogenic and Tumor-targeting Properties of TM601 at American Society of Clinical Oncology Annual Meeting 5/21/2009 9:25:54 AM
TransMolecular, Inc. Presents New Information on Distinct Anti-Angiogenic Mechanism-of-Action of TM601 5/4/2009 11:00:26 AM
TransMolecular, Inc. Announces Presentation of Data Confirming Anti-angiogenic Method-of-Action of TM601 at ARVO Annual Meeting 4/30/2009 11:32:03 AM
TransMolecular, Inc. Appoints Robert Radie President and Chief Executive Officer 4/7/2009 7:22:23 AM
TransMolecular, Inc. Receives Orphan Drug Designation for 131I-TM601 for the Treatment of Melanoma 12/22/2008 9:32:24 AM
TransMolecular, Inc. Reaches Special Protocol Agreement with FDA for an 131I-TM601 Phase 3 Trial in Newly Diagnosed Glioblastoma Multiforme Patients 12/2/2008 6:25:23 AM
1234
//-->